文献速递间质性肺疾病

年轻小鼠肺纤维化发展与消退过程中脂成纤维细胞向Cthrc1+肌成纤维细胞的可逆转换证据

Evidence for a lipofibroblast-to-Cthrc1 + myofibroblast reversible switch during the development and resolution of lung fibrosis in young mice.
PubMed 文献 · Eur Respir J · 2025-02-06

该研究结合遗传谱系追踪、单细胞转录组学、人类IPF数据集挖掘及类器官培养,在小鼠中探究活化肌成纤维细胞(aMYFs)的异质性及纤维化消退时的分化轨迹。研究发现aMYFs包含四个亚群,具有促肺泡生成或促纤维化特征;高表达脂成纤维细胞(LIF)样特征群的肺泡成纤维细胞主要构成aMYFs的来源和归宿,该异质性在人类中保守。

要点

  • aMYFs存在四个亚群,分别呈现促肺泡生成或促纤维化特征。
  • 高LIF样特征的肺泡成纤维细胞是纤维化形成时aMYFs的主要来源及消退时的归宿。
  • aMYFs异质性在人类中保守,部分人aMYFs高表达LIF特征。

核心结论

  • 鉴定出aMYFs的一个亚群,可能对IPF的未来管理具有潜在相关性。

研究设计与样本

  • 研究结合小鼠遗传谱系追踪和单细胞转录组学,并挖掘人类IPF数据集。
  • 利用类器官培养作为小鼠损伤修复不同阶段肺泡间充质生态位活性的功能读出。

主要发现

  • aMYFs由四个亚群组成,显示独特的促肺泡生成与促纤维化特征。
  • 高LIF样特征的肺泡成纤维细胞主要构成纤维化形成时aMYFs的来源和消退时的归宿。
  • aMYFs异质性在人类中保守,相当比例的人aMYFs显示高LIF特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibrosis is often associated with aberrant repair mechanisms that ultimately lead to organ failure. In the lung, idiopathic pulmonary fibrosis (IPF) is a fatal form of interstitial lung disease for which there is currently no curative therapy. From the cell biology point of view, the cell of origin and eventual fate of activated myofibroblasts (aMYFs) have taken centre stage, as these cells are believed to drive structural remodelling and lung function impairment. While aMYFs are now widely believed to originate from alveolar fibroblasts, the heterogeneity and ultimate fate of aMYFs during fibrosis resolution remain elusive. We have shown previously that aMYF dedifferentiation and acquisition of a lipofibroblast (LIF)-like phenotype represent a route of fibrosis resolution. METHODS: In this study, we combined genetic lineage tracing and single-cell transcriptomics in mice, and data mining of human IPF datasets to decipher the heterogeneity of aMYFs and investigate differentiation trajectories during fibrosis resolution. Furthermore, organoid cultures were utilised as a functional readout for the alveolar mesenchymal niche activity during various phases of injury and repair in mice. RESULTS: Our data demonstrate that aMYFs consist of four subclusters displaying unique pro-alveologenic versus pro-fibrotic profiles. Alveolar fibroblasts displaying a high LIF-like signature largely constitute both the origin and fate of aMYFs during fibrogenesis and resolution, respectively. The heterogeneity of aMYFs is conserved in humans and a significant proportion of human aMYFs displays a high LIF signature. CONCLUSION: Our work identifies a subcluster of aMYFs that is potentially relevant for future management of IPF.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Lingampally A, Truchi M, Mauduit O, et al. Evidence for a lipofibroblast-to-Cthrc1 + myofibroblast reversible switch during the development and resolution of lung fibrosis in young mice. Eur Respir J. 2025. PMID: 39401861. doi:10.1183/13993003.00482-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。